Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond

Lung cancer is the leading cause of cancer-related mortality in both sexes, accounting for over one quarter of cancer deaths. Non-small-cell lung cancer (NSCLC) comprises 85%–90% of lung cancer diagnoses and despite advances in multimodality therapies, 5-year survival rates remain dismal with a medi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Kanaan, Zeyad, Kloecker, Goetz H, Paintal, Ajit, Perez, Cesar A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2015
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4408973/
https://ncbi.nlm.nih.gov/pubmed/25945060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S67262
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller